Study of amivantamab plus standard care for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have head and neck cancer that has come back or spread and cannot be cured with local treatments.
- Your cancer must be in the mouth, throat, voice box, or lower throat (not the nasopharynx or unknown origin).
- You must not have had any previous drug treatment for cancer that has spread.
- You must be in good enough general health to carry out daily activities (ECOG score 0 or 1).
- Your cancer must be measurable on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This trial tests a new drug (amivantamab) combined with two chemotherapy drugs (carboplatin and paclitaxel) for people with head and neck cancer that has spread or come back after treatment and cannot be removed by surgery. This study aims to see if this combination can help shrink tumors.
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.